Romidepsin Plus Liposomal Doxorubicin Is Safe and Effective in Patients with Relapsed or Refractory T-Cell Lymphoma: Results of a Phase I Dose-Escalation StudyKhoan Vu, Weiyun Z. Ai, Frank McCormick et al.|Clinical Cancer Research|2019Cited by 40
Carfilzomib in Combination With Bendamustine and Rituximab in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma: A Phase I TrialSwetha Kambhampati, Charalambos Andreadis, Bita Fakhri et al.|Clinical Lymphoma Myeloma & Leukemia|2020Cited by 8
Table and Fig from Romidepsin Plus Liposomal Doxorubicin Is Safe and Effective in Patients with Relapsed or Refractory T-Cell Lymphoma: Results of a Phase I Dose-Escalation StudyKhoan Vu, Weiyun Z. Ai, Chi-Heng Wu et al.|Unknown|2023Cited by 0
Data from Romidepsin Plus Liposomal Doxorubicin Is Safe and Effective in Patients with Relapsed or Refractory T-Cell Lymphoma: Results of a Phase I Dose-Escalation StudyKhoan Vu, Weiyun Z. Ai, Chi-Heng Wu et al.|Unknown|2023Cited by 0
Data from Romidepsin Plus Liposomal Doxorubicin Is Safe and Effective in Patients with Relapsed or Refractory T-Cell Lymphoma: Results of a Phase I Dose-Escalation StudyKhoan Vu, Weiyun Z. Ai, Chi-Heng Wu et al.|Unknown|2023Cited by 0